Effects of immunocastration on performance and nitrogen utilization of Iberian pigs
Immunocastration -vaccination against gonadotropin releasing hormone (GnRH)- has been shown to prevent sexual development and boar taint in pigs being a feasible alternative to surgical castration (SC). Studies in conventional pigs point out that immunocastrated (IC) pigs show better performance than SC pigs. Apart from the benefits on animal welfare, this fact could be of interest for Iberian pigs and other fatty pig types, characterized by long productive cycles and low capacity for lean tissue growth. There is a question on whether protein requirements might be increased in IC compared to SC Iberian pigs. The purpose of this study was to examine the effects of immunocastration on Iberian pig growth and nitrogen (N) retention under 3 dietary protein concentrations. Fifty-four pure Iberian pigs were used (3 sexes: IC males, IC females, SC males; 3 isoenergetic diets: 150, 130 and 110 g CP/kg DM, 6 pigs/treatment combination). Vaccination against GnRH was at 4.3 (40 kg) and 6 months of age (70-80 kg). Pigs were individually housed consuming the experimental diets from 40 to 105 kg- BW with a slight restriction. Digestibility and N balance assays were performed at 50 and 90 kg BW, respectively. The IC males showed higher overall growth rate (+13%; P<0.001) and feed efficiency (+9.6%; P<0.001) than SC males and IC females, and slightly higher daily feed intake (+3%, P<0.001). No significant effect of dietary protein level was found on growth or feed efficiency. Before the second vaccination, IC pigs showed higher N retention (13 to 39%; P<0.001) and efficiency of N utilization (22 to 47%; P<0.001) than SC males and IC females. Pigs fed the lower protein content diet retained less N (P<0.05). However, no significant differences among sex groups in N retention parameters were detected after the second vaccination. Higher performance of IC male pigs seems to be related to a greater capacity for N retention before receiving the second dose of the vaccine. Funded by European Union's H2020 RIA program ...